• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Structure Therapeutics Inc.

    11/14/24 9:33:27 AM ET
    $GPCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GPCR alert in real time by email
    SC 13G/A 1 p24-3030sc13ga.htm STRUCTURE THERAPEUTICS INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    Structure Therapeutics Inc.

    (Name of Issuer)
     

    Ordinary Shares, par value $0.0001 per share

    (Title of Class of Securities)
     

    86366E106**

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    þ Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    **There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 86366E106 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on the NASDAQ under the trading symbol “GPCR.” Each ADS represents three (3) Ordinary Shares.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    CUSIP No. 86366E10613G/APage 2 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

    Avoro Capital Advisors LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) þ

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    OO, IA

             

     

     

     

     

    CUSIP No. 86366E10613G/APage 3 of 7 Pages

     

    1

    NAME OF REPORTING PERSON

    Behzad Aghazadeh

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) þ

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     

     

    CUSIP No. 86366E10613G/APage 4 of 7 Pages

     

    Item 1(a). NAME OF ISSUER
       
      Structure Therapeutics Inc. (the “Issuer”)

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
       
      601 Gateway Blvd., Suite 900, South San Francisco, California 94080

     

    Item 2(a). NAME OF PERSON FILING
       
      This statement is filed by: (i) Avoro Capital Advisors LLC, a Delaware limited liability company (“Avoro”), which provides investment advisory and management services and has acquired the securities of the Issuer solely for investment purposes on behalf of Avoro Life Sciences Fund LLC, a Delaware limited liability company, and (ii) Behzad Aghazadeh (“Dr. Aghazadeh,” and together with Avoro, the “Reporting Persons”), who serves as the portfolio manager and controlling person of Avoro.
       
      The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
       
      The address of the business office of each of the Reporting Persons is 110 Greene Street, Suite 800, New York, NY 10012.

     

    Item 2(c). CITIZENSHIP
       
      Avoro is a Delaware limited liability company.  Dr. Aghazadeh is a United States citizen.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
       
      Ordinary shares, par value $0.0001 per share (the “Ordinary Shares”)

     

    Item 2(e). CUSIP NUMBER
       
      86366E106

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;

     

    CUSIP No. 86366E10613G/APage 5 of 7 Pages

     

      (e) þ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) þ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please
      specify the type of institution:  

     

    Item 4. OWNERSHIP
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page and is incorporated herein by reference.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
       
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☑

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
       
      Not applicable.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
       
      Not applicable.

     

    CUSIP No. 86366E10613G/APage 6 of 7 Pages

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
       
      Not applicable.

     

    Item 10. CERTIFICATION
      Each Reporting Person hereby makes the following certification:
       
      By signing below the Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 86366E10613G/APage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: November 14, 2024

     

    AVORO CAPITAL ADVISORS LLC  
       
       
    /s/ Scott Epstein  
    Name: Scott Epstein  
    Title:

    Chief Financial Officer

    & Chief Compliance Officer

     
       
    /s/ Behzad Aghazadeh  
    BEHZAD AGHAZADEH  

     

    Get the next $GPCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GPCR

    DatePrice TargetRatingAnalyst
    5/2/2025$60.00Buy
    Citigroup
    2/28/2025Outperform
    William Blair
    1/8/2025$50.00Buy
    Stifel
    12/4/2024$80.00Buy
    H.C. Wainwright
    9/23/2024$118.00Overweight
    Morgan Stanley
    5/21/2024$65.00Overweight
    JP Morgan
    4/9/2024$65.00Overweight
    Cantor Fitzgerald
    10/19/2023$90.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $GPCR
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Structure Therapeutics Inc.

      SCHEDULE 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

      5/15/25 8:42:28 AM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Structure Therapeutics Inc.

      SCHEDULE 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

      5/14/25 12:32:44 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Structure Therapeutics Inc.

      SCHEDULE 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

      5/13/25 11:32:29 AM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GPCR
    Financials

    Live finance-specific insights

    See more
    • Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

      Preclinical studies with ACCG-2671 demonstrate potent target engagement, robust weight loss, favorable safety profile and PK properties supportive of once-daily dosing in humans ACCG-2671 is the most advanced oral small molecule amylin-based drug candidate, with Phase 1 study initiation expected by year end 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced the selection of its lead oral small molecule amylin receptor agonist, ACCG-2671. Amy

      12/17/24 4:01:00 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights

      First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be selected by the end of 2024 Strong financial position with cash, cash equivalent and short-term investments of $915.3 million expected to fund projected operations and key clinical milestones through at least 2027 Conference Call to discuss GSBR-1290 ACCESS development program today at 4:30 p.m. ET SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today

      11/13/24 4:05:00 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

      Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks Comprehensive development program also includes Phase 2 ACCESS II study to evaluate even higher doses of GSBR-1290 over 36 weeks; first patient expected to be dosed by end of 2024 Topline data from both ACCESS and ACCESS II studies expected in the fourth quarter of 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the first pati

      11/13/24 4:01:00 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GPCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

      SAN FRANCISCO, May 29, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences in June. Jefferies Global Healthcare Conference Format: Fireside chat and 1x1 meetingsDate/time: Thursday, June 5 at 8:10 a.m. ETLocation: New York, NY Goldman Sachs Global Healthcare Conference Format: Fireside chat and 1x1 meetingsDate/time: Wednesday, June 11 at 10:40 a.m. ETLocation: Miami, FL The live and archived webcasts of the fireside chats will be accessible from the compa

      5/29/25 4:05:00 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights

      Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Investigational New Drug (IND)-enabling activities underway; First-in-human Phase 1 initiation anticipated by year-end 2025 Strong year-end financial position with cash, cash equivalent and short-term investments of $883.5 million SAN FRANCISCO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today reported financial results for the fourth quarter and f

      2/27/25 4:05:00 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

      SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences being held in February and March. Guggenheim SMID Cap Biotech Conference  Format:Fireside chat and 1x1 meetings Date/time:Wednesday, February 5 at 10:30 a.m. ET Location:New York, NY Webcast link:https://wsw.com/webcast/guggen2/gpcr/2003892    Leerink Global Healthcare Conference  Format:Fireside chat and 1x1 meetings Date/time:Monday, March 10 at 1:00 p.m. ET 

      1/30/25 8:30:00 AM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GPCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Structure Therapeutics with a new price target

      Citigroup initiated coverage of Structure Therapeutics with a rating of Buy and set a new price target of $60.00

      5/2/25 8:15:19 AM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • William Blair initiated coverage on Structure Therapeutics

      William Blair initiated coverage of Structure Therapeutics with a rating of Outperform

      2/28/25 7:24:16 AM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Structure Therapeutics with a new price target

      Stifel initiated coverage of Structure Therapeutics with a rating of Buy and set a new price target of $50.00

      1/8/25 7:51:31 AM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GPCR
    Leadership Updates

    Live Leadership Updates

    See more
    • Structure Therapeutics Strengthens Executive Team with Promotion of Blai Coll, M.D., Ph.D. to Chief Medical Officer and Appointment of Ashley Hall, J.D. as Chief Development Officer

      SAN FRANCISCO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced key leadership appointments to drive its next phase of development and operational success. Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D., Ph.D. as part of a planned succession, effective September 18. Dr. Coll has served as Vice President of Clinical Development at Structure since 2022, leading the GSBR-1290 program, Structure's oral small molecule GLP-1 agonist that is planned to enter Phase

      9/17/24 4:05:00 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Structure Therapeutics Appoints Angus C. Russell to Board of Directors

      SAN FRANCISCO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the appointment of Angus C. Russell to its board of directors. Mr. Russell previously served as Chief Executive Officer of Shire plc and brings more than 30 years of experience in building and scaling companies in the global biopharmaceutical industry. "Structure is at an important moment in its evolution as we prepare to advance our oral small molecule GLP-1 agonist, GSBR-1290, into late-stage clinical development for obesity," said Raymond Steve

      8/27/24 4:05:00 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights

      Completed enrollment in 12-week Phase 2a study of oral GLP-1 receptor agonist, GSBR-1290 Topline data from Phase 2a and Phase 1b multiple ascending dose study of GSBR-1290 expected in latter half of fourth quarter 2023 SAN FRANCISCO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the second quarter June 30, 2023, and highlighted recent corporate achievements. "We have continued our momentum and are on track to report topline data from our fully-enrolled Phase 2a study of GSBR-129

      8/10/23 4:05:00 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GPCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Structure Therapeutics Inc.

      SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

      11/14/24 5:46:12 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Structure Therapeutics Inc.

      SC 13G - Structure Therapeutics Inc. (0001888886) (Subject)

      11/14/24 10:26:11 AM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Structure Therapeutics Inc.

      SC 13G/A - Structure Therapeutics Inc. (0001888886) (Subject)

      11/14/24 9:33:27 AM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GPCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Development Officer Hall Ashley was granted 51,048 units of Ordinary Shares, increasing direct ownership by 76% to 118,338 units (SEC Form 4)

      4 - Structure Therapeutics Inc. (0001888886) (Issuer)

      3/18/25 8:45:14 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF TECHNOLOGY OFFICER Ma Yingli was granted 63,810 units of Ordinary Shares, increasing direct ownership by 174% to 100,539 units (SEC Form 4)

      4 - Structure Therapeutics Inc. (0001888886) (Issuer)

      3/18/25 8:45:12 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Coll Crespo Blas was granted 116,988 units of Ordinary Shares, increasing direct ownership by 114% to 219,588 units (SEC Form 4)

      4 - Structure Therapeutics Inc. (0001888886) (Issuer)

      3/18/25 8:45:17 PM ET
      $GPCR
      Biotechnology: Pharmaceutical Preparations
      Health Care